Applied Therapeutics Financial Statements (APLT)
|
|
|
|
Report date
|
|
|
18.03.2021 |
10.03.2022 |
23.03.2023 |
06.03.2024 |
15.04.2025 |
|
13.11.2025 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
9.99 |
0.455 |
|
1.000 |
|
Operating Income, bln rub |
|
|
-94.5 |
-105.6 |
-83.0 |
-64.5 |
-104.3 |
|
-98.4 |
|
EBITDA, bln rub |
? |
|
-94.5 |
-105.6 |
-82.1 |
-64.5 |
-105.6 |
|
-100.5 |
|
Net profit, bln rub |
? |
|
-94.0 |
-105.6 |
-82.5 |
-119.8 |
-105.6 |
|
-18.1 |
|
|
OCF, bln rub |
? |
|
-78.2 |
-90.7 |
-78.1 |
-55.2 |
-84.3 |
|
-86.8 |
|
CAPEX, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
FCF, bln rub |
? |
|
-78.2 |
-90.7 |
-78.1 |
-55.2 |
-84.3 |
|
-86.8 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
|
|
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
|
OPEX, bln rub |
|
|
94.5 |
105.6 |
82.5 |
20.6 |
56.0 |
|
69.9 |
|
Cost of production, bln rub |
|
|
0.000 |
0.000 |
0.441 |
53.9 |
48.7 |
|
29.5 |
|
R&D, bln rub |
|
|
61.8 |
62.6 |
55.6 |
53.9 |
48.7 |
|
39.1 |
|
Interest expenses, bln rub |
|
|
0.559 |
0.555 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Assets, bln rub |
|
|
104.5 |
89.9 |
38.4 |
54.8 |
86.7 |
|
34.4 |
|
Net Assets, bln rub |
? |
|
81.9 |
62.5 |
4.06 |
-17.1 |
57.0 |
|
-0.561 |
|
Debt, bln rub |
|
|
2.81 |
2.12 |
1.98 |
0.777 |
2.80 |
|
2.50 |
|
Cash, bln rub |
|
|
96.8 |
80.8 |
30.6 |
49.9 |
79.4 |
|
11.9 |
|
Net debt, bln rub |
|
|
-94.0 |
-78.7 |
-28.6 |
-49.1 |
-76.6 |
|
-9.45 |
|
|
Ordinary share price, rub |
|
|
22.0 |
8.95 |
|
|
0.856 |
|
0.605 |
|
Number of ordinary shares, mln |
|
|
22.0 |
25.6 |
37.8 |
84.2 |
139.5 |
|
145.6 |
|
|
Market cap, bln rub |
|
|
483 |
229 |
0 |
0 |
119 |
|
88 |
|
EV, bln rub |
? |
|
389 |
150 |
-29 |
-49 |
43 |
|
79 |
|
Book value, bln rub |
|
|
82 |
63 |
4 |
-17 |
57 |
|
-1 |
|
|
EPS, rub |
? |
|
-4.28 |
-4.12 |
-2.18 |
-1.42 |
-0.76 |
|
-0.12 |
|
FCF/share, rub |
|
|
-3.56 |
-3.54 |
-2.06 |
-0.65 |
-0.60 |
|
-0.60 |
|
BV/share, rub |
|
|
3.73 |
2.44 |
0.11 |
-0.20 |
0.41 |
|
0.00 |
|
|
EBITDA margin, % |
? |
|
|
|
|
-645.8% |
-23 214% |
|
-10 052% |
|
Net margin, % |
? |
|
|
|
|
-1 198% |
-23 214% |
|
-1 814% |
|
FCF yield, % |
? |
|
-16.2% |
-39.6% |
|
|
-70.6% |
|
-98.6% |
|
ROE, % |
? |
|
-114.7% |
-168.8% |
-2 032% |
698.5% |
-185.3% |
|
3 233% |
|
ROA, % |
? |
|
-89.9% |
-117.5% |
-215.1% |
-218.4% |
-121.8% |
|
-52.8% |
|
|
P/E |
? |
|
-5.15 |
-2.17 |
0.00 |
0.00 |
-1.13 |
|
-4.85 |
|
P/FCF |
|
|
-6.18 |
-2.53 |
0.00 |
0.00 |
-1.42 |
|
-1.01 |
|
P/S |
? |
|
|
|
|
0.00 |
262.6 |
|
88.0 |
|
P/BV |
? |
|
5.90 |
3.66 |
0.00 |
0.00 |
2.10 |
|
-157.0 |
|
EV/EBITDA |
? |
|
-4.12 |
-1.42 |
0.35 |
0.76 |
-0.41 |
|
-0.78 |
|
Debt/EBITDA |
|
|
1.00 |
0.75 |
0.35 |
0.76 |
0.73 |
|
0.09 |
|
|
CAPEX/Revenue, % |
|
|
|
|
|
0.00% |
0.00% |
|
0.00% |
|
| Applied Therapeutics shareholders |
